Latest news

• Detailed results for Regeneron's antibody cocktail continue to show benefit in high-risk COVID-19 outpatients

  Regeneron’s antibody cocktail REGEN-COV cuts the risk of hospitalisation or death by 70% in non-hospitalised COVID-19 patients, according to detailed phase 3 trial results. ... Roche is primarily responsible for the development and distribution of the

• Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments

  In addition to Bourla, Regeneron’s CEO Leonard Schleifer also said he expects an “ongoing global need” for COVID-19 therapeutics, such as the company’s monoclonal antibody treatment REGEN-COV. ... In the US, the antibody cocktail is approved for

• Roche, Regeneron’s COVID-19 antibody cocktail cuts infection risk

  Roche and Regeneron’s COVID-19 antibody cocktail REGEN-COV reduced the risk of symptomatic infections by 81% in a phase 3 prevention trial. ... 90%. "With more than 60, 000 Americans continuing to be diagnosed with COVID-19 every day, the REGEN-COV

• Pfizer launches early study of COVID-19 antiviral therapeutic

  Regeneron’s antibody cocktail ( casirivimab and imdevimab) has been granted an emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) for the treatment of certain mild-to-moderate ... Lilly’s monoclonal antibody (mAb)

• Roche, Regeneron’s COVID-19 antibody cocktail cuts hospitalisation or death by 70%

  Roche and Regeneron’s COVID-19 antibody cocktail has demonstrated positive results in a phase 3 trial assessing the investigational treatment in infected non-hospitalised patients. ... treatment. At the beginning of February, the EMA launched a rolling